Semaglutide SM
GLP-1R agonist
Long-acting GLP-1 receptor agonist, a modified analogue of the native hormone, studied for insulin secretion and appetite pathways.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GLP-1R agonist
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- SM
- Development and regulatory status
- Approved prescription drug (type 2 diabetes, obesity)
What researchers study
Semaglutide is a long-acting GLP-1 receptor agonist, a modified analogue of the native hormone with extended duration of action. Researchers study its effects on glucose-dependent insulin secretion and on appetite and food-intake pathways.
Research areas
- GLP-1 receptor signalling in cells and animals
- Glucose-dependent insulin secretion studies
- Appetite and food-intake pathway research
- Cardiometabolic outcome research
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In 1,961 adults with overweight or obesity and no diabetes, mean weight change at 68 weeks was -14.9% versus -2.4% with placebo
- phase 3 trial
In SELECT, 17,604 adults with overweight or obesity and cardiovascular disease had a hazard ratio of 0.80 for the primary cardiovascular composite versus placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Cagrilintideamylin analogue combined with semaglutide in CagriSema studies
- CagriSemacatalogue combination of cagrilintide and semaglutide
- Tirzepatidedual agonist often compared with semaglutide in incretin pharmacology
